Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

Abstract Number: 0423 • ACR Convergence 2023
Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Sara Charmsaz¹, Jeff Tracy¹, Elizabeth Whalen¹, John Bui¹, Anne-Renee van der Vuurst de Vries¹, Vivianne Malmström² and Michelle Blake¹, ¹Sonoma Biotherapeutics, Seattle, WA, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0730 • ACR Convergence 2023
NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis
Giulia Frazzei¹, Jan Piet van Hamburg², Ronald van Vollenhoven² and Sander Tas³, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis, and their presence is associated with disease severity. Consequently, detailed analysis of…
Abstract Number: 2583 • ACR Convergence 2023
A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia
Klára Prajzlerová¹, Olga Kryštůfková², Nikola Kaspříková³, Nora Růžičková², Hana Hulejová¹, Petra Hánová¹, Jiri Vencovsky⁴, Ladislav Senolt⁵ and Maria Filkova², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) substantially increases the risk of developing rheumatoid arthritis (RA). The definition of individuals with arthralgia at…
Abstract Number: 1139 • ACR Convergence 2023
From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic
Leeany Maletta¹, Diana Jimenez² and Rosanna de Jesus³, ¹UNIBE School of Medicine, San Antonio, TX, ²UNIBE School of Medicine, Miami, FL, ³Hospital General Plaza de la Salud, Distrito Nacional, Dominican Republic
Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…
Abstract Number: 1727 • ACR Convergence 2023
Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are…
Abstract Number: 1728 • ACR Convergence 2023
A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
Abstract Number: 1737 • ACR Convergence 2023
ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA
Veerle Derksen¹, Klara Martinsson², René Toes¹, Daniel Sjöberg³, Thomas Huizinga¹, Alf Kastbom⁴, Anna Svärd³ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Linköping University, Linköping, Sweden, ³Centre for Clinical Research Dalarna, Uppsala, Sweden, ⁴Linköping University, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1748 • ACR Convergence 2023
Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies
S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
Abstract Number: 1417 • ACR Convergence 2022
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Gordon Lam¹, Hanke Zheng², Emily Bland³, Vardhaman Patel⁴, Laetitia N’Dri⁵, Parisa Asgarisabet³, Keith Wittstock⁴, Cherrishe Brown-Bickerstaff³, Mark Chaballa², Bruce Feinberg³, Vadim Khaychuk⁶ and Andrew J Klink³, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Cardinal Health, Dublin, OH, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Princeton, ⁶Bristol Myers Squibb, Pennington, MA
Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
Abstract Number: 1685 • ACR Convergence 2022
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Alexandra Taylor¹, Michael Duryee², Carlos Hunter², nozima Aripova², Ted Mikuls³ and Geoffrey Thiele², ¹Creighton University School of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
Abstract Number: 1965 • ACR Convergence 2022
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
Hsin-Yi Peng¹, Ting-Yin Xue¹, Fei-Hung Hsieh¹, Yi-Ko Chen¹, Mei-Chin Yin², Che-Yi Chao², Shu-Yao Tsai², Chung-Ping Lin³, Po-Hao Huang³, Chien-Chung Huang³, Jiunn-Horng Chen³, Chung-Ming Huang³, Der-Yuan Chen⁴, Joung-Liang Lan⁵ and Gregory Tsay³, ¹China Medical University, Taichung, Taiwan, ²Asia University, Taichung, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, ⁵China Medoical University Hospital, Taichung, Taiwan
Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
Abstract Number: 1968 • ACR Convergence 2022
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Nora Petrovská², Petra Hánová¹, Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.